AGP Executive Report
Last update: 8 hours agoCancer Immunotherapy Breakthroughs: Taiwan’s Tang Prize 2026 Biopharmaceutical Science honors Steven A. Rosenberg, Michel Sadelain, and Carl H. June for tumor-infiltrating lymphocyte (TIL) and CAR-T therapies, spotlighting how “living drugs” can turn a patient’s immune system into cancer-fighting medicine. Drug Licensing for Kidney Disease: Dimerix signed an exclusive license with Everest Medicines to commercialize DMX-200 (all indications, including focal segmental glomerulosclerosis) across Greater China, Taiwan, South Korea, and parts of Southeast Asia, with a US$10M upfront payment and up to US$330M in milestones plus 10–15% royalties. Infant Formula Safety Check: Taiwan TFDA said a suspected U.S. infant botulism-linked formula (Nara Organics Whole Milk Infant Formula) has not been imported into Taiwan for at least three years and is not registered locally; consumers were urged to watch for botulism symptoms. Wellness Market Trend in Malaysia: A June 23 Global Wellness Forum in Kuala Lumpur will focus on next-gen nutraceuticals, with Taiwanese R&D teams highlighting “food-like” supplement formats such as Halal-certified FRESH-Jelly. AI in Healthcare Dispatch Raises Questions: A Seattle Fire Department case reports AI used to triage 911 medical calls without caller disclosure, raising concerns about transparency and oversight. Health Tech & Infrastructure: Schneider Electric and Foxconn announced collaboration to scale next-gen AI data centers, aiming to speed deployment of power and cooling systems that underpin healthcare AI growth.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
